{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:54:17Z","timestamp":1791413657222,"version":"4.3.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020410","name":"T\u00fcrkiye Sa\u011fl\u0131k Enstit\u00fcleri Ba\u015fkanl\u0131\u011f\u0131","doi-asserted-by":"publisher","award":["37247"],"award-info":[{"award-number":["37247"]}],"id":[{"id":"10.13039\/100020410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020410","name":"T\u00fcrkiye Sa\u011fl\u0131k Enstit\u00fcleri Ba\u015fkanl\u0131\u011f\u0131","doi-asserted-by":"publisher","award":["37247"],"award-info":[{"award-number":["37247"]}],"id":[{"id":"10.13039\/100020410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020410","name":"T\u00fcrkiye Sa\u011fl\u0131k Enstit\u00fcleri Ba\u015fkanl\u0131\u011f\u0131","doi-asserted-by":"publisher","award":["37247"],"award-info":[{"award-number":["37247"]}],"id":[{"id":"10.13039\/100020410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020410","name":"T\u00fcrkiye Sa\u011fl\u0131k Enstit\u00fcleri Ba\u015fkanl\u0131\u011f\u0131","doi-asserted-by":"publisher","award":["37247"],"award-info":[{"award-number":["37247"]}],"id":[{"id":"10.13039\/100020410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-61057-w","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:07:53Z","timestamp":1783480073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of hesperidin, nanohesperidin and obeticholic acid on hepatic FXR and SMAD3 in HFD\/fructose-fed mice"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-0231","authenticated-orcid":false,"given":"Ay\u015feg\u00fcl","family":"Sivasl\u0131o\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2800-0240","authenticated-orcid":false,"given":"G\u00fclcan Uysal","family":"Yeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1599-7926","authenticated-orcid":false,"given":"S\u00fcleyman Can","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-276X","authenticated-orcid":false,"given":"Tu\u011fba","family":"G\u00fcls\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-5512","authenticated-orcid":false,"given":"Mustafa","family":"\u00c7elebier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7241-8017","authenticated-orcid":false,"given":"Zeynep","family":"G\u00f6kta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"61057_CR1","doi-asserted-by":"publisher","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78:1966. (2023). https:\/\/doi.org\/10.1097\/HEP.0000000000000520","DOI":"10.1097\/HEP.0000000000000520"},{"key":"61057_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao, L. et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol. Metab. 35, 697\u2013707. https:\/\/doi.org\/10.1016\/j.tem.2024.02.007 (2024).","journal-title":"Trends Endocrinol. Metab."},{"key":"61057_CR3","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1097\/CM9.0000000000003517","volume":"138","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Global burden of metabolic-associated fatty liver disease: A systematic analysis of Global Burden of Disease Study 2021. Chin. Med. J. (Engl). 138, 2947\u20132954. https:\/\/doi.org\/10.1097\/CM9.0000000000003517 (2025).","journal-title":"Chin. Med. J. (Engl)"},{"key":"61057_CR4","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.3390\/cells11213425","volume":"11","author":"MD Chiang Morales","year":"2022","unstructured":"Chiang Morales, M. D. et al. High-fructose\/high-fat diet downregulates the hepatic mitochondrial oxidative phosphorylation pathway in mice compared with high-fat diet alone. Cells 11, 3425. https:\/\/doi.org\/10.3390\/cells11213425 (2022).","journal-title":"Cells"},{"key":"61057_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3390\/life14060729","volume":"14","author":"Z Ding","year":"2024","unstructured":"Ding, Z., Zhang, J. & Choudhury, M. A high-fat and high-fructose diet exacerbates liver dysfunction by regulating sirtuins in a murine model. Life 14, 729. https:\/\/doi.org\/10.3390\/life14060729 (2024).","journal-title":"Life"},{"key":"61057_CR6","doi-asserted-by":"publisher","unstructured":"Yustisia, I. et al. A high-fat, high-fructose diet induced hepatic steatosis, renal lesions, dyslipidemia, and hyperuricemia in non-obese rats. Heliyon 8 https:\/\/doi.org\/10.1016\/j.heliyon.2022.e10896 (2022).","DOI":"10.1016\/j.heliyon.2022.e10896"},{"key":"61057_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.14218\/JCTH.2025.00029","volume":"13","author":"W Zhu","year":"2025","unstructured":"Zhu, W. et al. Exploring the therapeutic potential of TGF-\u03b2 inhibitors for liver fibrosis: Targeting multiple signaling pathways. J. Clin. Transl Hepatol. 13, 588\u2013598. https:\/\/doi.org\/10.14218\/JCTH.2025.00029 (2025).","journal-title":"J. Clin. Transl Hepatol."},{"key":"61057_CR8","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.14336\/AD.2023.0830","volume":"15","author":"C Ding","year":"2024","unstructured":"Ding, C. et al. Farnesoid X receptor: From structure to function and its pharmacology in liver fibrosis. Aging Dis. 15, 1508\u20131536. https:\/\/doi.org\/10.14336\/AD.2023.0830 (2024).","journal-title":"Aging Dis."},{"key":"61057_CR9","doi-asserted-by":"publisher","first-page":"116658","DOI":"10.1016\/j.biopha.2024.116658","volume":"175","author":"Y Tang","year":"2024","unstructured":"Tang, Y. et al. A current understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development. Biomed. Pharmacother. 175, 116658. https:\/\/doi.org\/10.1016\/j.biopha.2024.116658 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"61057_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.phrs.2018.02.033","volume":"131","author":"A Carino","year":"2018","unstructured":"Carino, A. et al. Disruption of TFG\u03b2-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand. Pharmacol. Res. 131, 17\u201331. https:\/\/doi.org\/10.1016\/j.phrs.2018.02.033 (2018).","journal-title":"Pharmacol. Res."},{"key":"61057_CR11","doi-asserted-by":"publisher","first-page":"105911","DOI":"10.1016\/j.intimp.2019.105911","volume":"77","author":"Y-Y Fan","year":"2019","unstructured":"Fan, Y-Y. et al. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. Int. Immunopharmacol. 77, 105911. https:\/\/doi.org\/10.1016\/j.intimp.2019.105911 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"61057_CR12","doi-asserted-by":"publisher","first-page":"118332","DOI":"10.1016\/j.ejmech.2025.118332","volume":"302","author":"Q Li","year":"2026","unstructured":"Li, Q. et al. FXR-targeted drug discovery: Recent advances and therapeutic perspectives. Eur. J. Med. Chem. 302, 118332. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118332 (2026).","journal-title":"Eur. J. Med. Chem."},{"key":"61057_CR13","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196. https:\/\/doi.org\/10.1016\/S0140-6736(19)33041-7 (2019).","journal-title":"Lancet"},{"key":"61057_CR14","doi-asserted-by":"publisher","first-page":"115777","DOI":"10.1016\/j.biopha.2023.115777","volume":"168","author":"A Azizsoltani","year":"2023","unstructured":"Azizsoltani, A. et al. Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling. Biomed. Pharmacother. 168, 115777. https:\/\/doi.org\/10.1016\/j.biopha.2023.115777 (2023).","journal-title":"Biomed. Pharmacother"},{"key":"61057_CR15","doi-asserted-by":"publisher","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","volume":"8","author":"T Goto","year":"2018","unstructured":"Goto, T. et al. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. Sci. Rep. 8, 8157. https:\/\/doi.org\/10.1038\/s41598-018-26383-8 (2018).","journal-title":"Sci. Rep."},{"key":"61057_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/ijms27020594","volume":"27","author":"I Saponara","year":"2026","unstructured":"Saponara, I. et al. Anti-fibrotic and anti-inflammatory effects of hesperidin in an ex vivo mouse model of early-onset liver fibrosis. Int. J. Mol. Sci. 27, 594. https:\/\/doi.org\/10.3390\/ijms27020594 (2026).","journal-title":"Int. J. Mol. Sci."},{"key":"61057_CR17","doi-asserted-by":"publisher","first-page":"115561","DOI":"10.1016\/j.fct.2025.115561","volume":"203","author":"J Li","year":"2025","unstructured":"Li, J. et al. Loperamide-induced constipation is associated with excessive accumulation of bile acids and cholesterol in the liver of mice; attenuation by hesperidin. Food Chem. Toxicol. Int. J. Publ Br. Ind. Biol. Res. Assoc. 203, 115561. https:\/\/doi.org\/10.1016\/j.fct.2025.115561 (2025).","journal-title":"Food Chem. Toxicol. Int. J. Publ Br. Ind. Biol. Res. Assoc."},{"key":"61057_CR18","doi-asserted-by":"publisher","first-page":"173498","DOI":"10.1016\/j.ejphar.2020.173498","volume":"885","author":"G Zhang","year":"2020","unstructured":"Zhang, G. et al. Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo. Eur. J. Pharmacol. 885, 173498. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173498 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"61057_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/ph17080999","volume":"17","author":"M Almukainzi","year":"2024","unstructured":"Almukainzi, M., El-Masry, T. A., El Zahaby, E. I. & El-Nagar, M. M. F. Chitosan\/hesperidin nanoparticles for sufficient, compatible, antioxidant, and antitumor drug delivery systems. Pharmaceuticals 17, 999. https:\/\/doi.org\/10.3390\/ph17080999 (2024).","journal-title":"Pharmaceuticals"},{"key":"61057_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/17425247.2025.2581839","volume":"23","author":"TPN Hoang","year":"2026","unstructured":"Hoang, T. P. N. et al. Drug delivery and formulation development of hesperidin: a systematic review. Expert Opin. Drug Deliv. 23, 363\u2013384. https:\/\/doi.org\/10.1080\/17425247.2025.2581839 (2026).","journal-title":"Expert Opin. Drug Deliv."},{"key":"61057_CR21","doi-asserted-by":"publisher","first-page":"100363","DOI":"10.1016\/j.prmcm.2024.100363","volume":"10","author":"K Bansal","year":"2024","unstructured":"Bansal, K., Bhati, H. & Vanshita, Bajpai, M. New insights into therapeutic applications and nanoformulation approaches of hesperidin: An updated review. Pharmacol. Res. Mod. Chin. Med. 10, 100363. https:\/\/doi.org\/10.1016\/j.prmcm.2024.100363 (2024).","journal-title":"Pharmacol. Res. Mod. Chin. Med."},{"key":"61057_CR22","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.fochx.2023.100639","volume":"18","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Preparation and in vitro evaluation of hesperidin nanoparticles by antisolvent recrystallization in a double homogenate system. Food Chem. X. 18, 100639. https:\/\/doi.org\/10.1016\/j.fochx.2023.100639 (2023).","journal-title":"Food Chem. X"},{"key":"61057_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.clnesp.2025.07.508","volume":"69","author":"A Sivasl\u0131o\u011flu","year":"2025","unstructured":"Sivasl\u0131o\u011flu, A. & G\u00f6kta\u015f, Z. Nanoformulated hesperidin reduces liver weight more effectively than free hesperidin: A comparative evaluation in a high-fat diet and fructose-induced metabolic liver disease model. Clin. Nutr. ESPEN. 69, 981. https:\/\/doi.org\/10.1016\/j.clnesp.2025.07.508 (2025).","journal-title":"Clin. Nutr. ESPEN"},{"key":"61057_CR24","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 18, e3000411. https:\/\/doi.org\/10.1371\/journal.pbio.3000411 (2020).","journal-title":"PLoS Biol."},{"key":"61057_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","volume":"23","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 23, 117. https:\/\/doi.org\/10.1186\/s12944-024-02108-x (2024).","journal-title":"Lipids Health Dis."},{"key":"61057_CR26","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.59717\/j.xinn-med.2024.100064","volume":"2","author":"M Zheng","year":"2024","unstructured":"Zheng, M. et al. New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: Findings from prospective cohort. Innov. Med. 2, 100064. https:\/\/doi.org\/10.59717\/j.xinn-med.2024.100064 (2024).","journal-title":"Innov. Med."},{"key":"61057_CR27","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.3390\/ijms26136518","volume":"26","author":"K Drygalski","year":"2025","unstructured":"Drygalski, K. Pharmacological treatment of MASLD: Contemporary treatment and future perspectives. Int. J. Mol. Sci. 26, 6518. https:\/\/doi.org\/10.3390\/ijms26136518 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"61057_CR28","doi-asserted-by":"publisher","first-page":"156271","DOI":"10.1016\/j.metabol.2025.156271","volume":"169","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. WWP1-SHARP1-C\/EBP\u03b2 positive feedback loop modulates development of metabolic dysfunction-associated steatotic liver disease. Metabolism 169, 156271. https:\/\/doi.org\/10.1016\/j.metabol.2025.156271 (2025).","journal-title":"Metabolism"},{"key":"61057_CR29","doi-asserted-by":"publisher","unstructured":"Cofano, M. et al. Hesperidin is a promising nutraceutical compound in counteracting the progression of NAFLD in vitro. Int. J. Mol. Sci. 26 https:\/\/doi.org\/10.3390\/ijms26135982 (2025).","DOI":"10.3390\/ijms26135982"},{"key":"61057_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS T\u00f8lb\u00f8l","year":"2018","unstructured":"T\u00f8lb\u00f8l, K. S. et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J. Gastroenterol. 24, 179\u2013194. https:\/\/doi.org\/10.3748\/wjg.v24.i2.179 (2018).","journal-title":"World J. Gastroenterol."},{"key":"61057_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70495","author":"Y Wang","year":"2026","unstructured":"Wang, Y. et al. Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features. Diabetes Obes. Metab. https:\/\/doi.org\/10.1111\/dom.70495 (2026).","journal-title":"Diabetes Obes. Metab."},{"key":"61057_CR32","doi-asserted-by":"publisher","first-page":"11224","DOI":"10.1021\/acs.jafc.2c02334","volume":"70","author":"X Li","year":"2022","unstructured":"Li, X. et al. Effect of hesperidin supplementation on liver metabolomics and gut microbiota in a high-fat diet-induced NAFLD mice model. J. Agric. Food Chem. 70, 11224\u201311235. https:\/\/doi.org\/10.1021\/acs.jafc.2c02334 (2022).","journal-title":"J. Agric. Food Chem."},{"key":"61057_CR33","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.2147\/DMSO.S474034","volume":"17","author":"T Liu","year":"2024","unstructured":"Liu, T. et al. Hesperidin and fecal microbiota transplantation modulate the composition of the gut microbiota and reduce obesity in high fat diet mice. Diabetes Metab. Syndr. Obes. 17, 3643\u20133656. https:\/\/doi.org\/10.2147\/DMSO.S474034 (2024).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"61057_CR34","doi-asserted-by":"publisher","unstructured":"Chen, T-C. et al. Thiolated chitosan as an intestinal absorption carrier with hesperidin encapsulation for obesity treatment. Nutrients 13 https:\/\/doi.org\/10.3390\/nu13124405 (2021).","DOI":"10.3390\/nu13124405"},{"key":"61057_CR35","doi-asserted-by":"publisher","first-page":"e14444","DOI":"10.1111\/jfbc.14444","volume":"46","author":"W Hanchang","year":"2022","unstructured":"Hanchang, W., Wongmanee, N., Yoopum, S. & Rojanaverawong, W. Protective role of hesperidin against diabetes induced spleen damage: Mechanism associated with oxidative stress and inflammation. J. Food Biochem. 46, e14444. https:\/\/doi.org\/10.1111\/jfbc.14444 (2022).","journal-title":"J. Food Biochem."},{"key":"61057_CR36","doi-asserted-by":"publisher","first-page":"723","DOI":"10.17179\/excli2019-1094","volume":"18","author":"Z Zhou","year":"2019","unstructured":"Zhou, Z., Kandhare, A. D., Kandhare, A. A. & Bodhankar, S. L. Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1\/Smad3\/AMPK and IkappaBalpha\/NF-kappaB pathways. EXCLI J. 18, 723\u2013745. https:\/\/doi.org\/10.17179\/excli2019-1094 (2019).","journal-title":"EXCLI J."},{"key":"61057_CR37","doi-asserted-by":"publisher","first-page":"118542","DOI":"10.1016\/j.biopha.2025.118542","volume":"192","author":"J Melek","year":"2025","unstructured":"Melek, J. et al. Obeticholic acid does not restore Western diet-induced alterations in hepatic mitochondrial respiration. Biomed. Pharmacother. Biomed. Pharmacother. 192, 118542. https:\/\/doi.org\/10.1016\/j.biopha.2025.118542 (2025).","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother"},{"key":"61057_CR38","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","volume":"61","author":"S Softic","year":"2016","unstructured":"Softic, S., Cohen, D. E. & Kahn, C. R. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig. Dis. Sci. 61, 1282\u20131293. https:\/\/doi.org\/10.1007\/s10620-016-4054-0 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"61057_CR39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye, Q. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 739\u2013752. https:\/\/doi.org\/10.1016\/S2468-1253(20)30077-7 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"61057_CR40","doi-asserted-by":"publisher","unstructured":"Dewidar, B., Meyer, C., Dooley, S. & Meindl-Beinker and N TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis\u2014Updated 2019. Cells 8:. (2019). https:\/\/doi.org\/10.3390\/cells8111419","DOI":"10.3390\/cells8111419"},{"key":"61057_CR41","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.3390\/ijms23116270","volume":"23","author":"T Yamaguchi","year":"2022","unstructured":"Yamaguchi, T. et al. Smad3 phospho-isoform signaling in nonalcoholic steatohepatitis. Int. J. Mol. Sci. 23, 6270. https:\/\/doi.org\/10.3390\/ijms23116270 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"61057_CR42","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00109-022-02248-6","volume":"100","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. TGF-\u03b21\/Smad3 upregulates UCA1 to promote liver fibrosis through DKK1 and miR18a. J. Mol. Med. 100, 1465\u20131478. https:\/\/doi.org\/10.1007\/s00109-022-02248-6 (2022).","journal-title":"J. Mol. Med."},{"key":"61057_CR43","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1478-3231.2009.02011.x","volume":"29","author":"G Latella","year":"2009","unstructured":"Latella, G. et al. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int. Off J. Int. Assoc. Study Liver. 29, 997\u20131009. https:\/\/doi.org\/10.1111\/j.1478-3231.2009.02011.x (2009).","journal-title":"Liver Int. Off J. Int. Assoc. Study Liver"},{"key":"61057_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cbi.2017.09.015","volume":"277","author":"AM Mahmoud","year":"2017","unstructured":"Mahmoud, A. M., Mohammed, H. M., Khadrawy, S. M. & Galaly, S. R. Hesperidin protects against chemically induced hepatocarcinogenesis via modulation of Nrf2\/ARE\/HO-1, PPAR\u03b3 and TGF-\u03b21\/Smad3 signaling, and amelioration of oxidative stress and inflammation. Chem. Biol. Interact. 277, 146\u2013158. https:\/\/doi.org\/10.1016\/j.cbi.2017.09.015 (2017).","journal-title":"Chem. Biol. Interact."},{"key":"61057_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227\u2013232. https:\/\/doi.org\/10.1038\/nrg3185 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"61057_CR46","doi-asserted-by":"publisher","first-page":"394632024130900","DOI":"10.1177\/03946320241309004","volume":"38","author":"A Megahed","year":"2024","unstructured":"Megahed, A. et al. Hesperidin ameliorates thioacetamide-induced liver fibrosis via antioxidative and anti-inflammatory mechanisms targeting TGF-\u03b2\/\u03b1-SMA pathways in rats. Int. J. Immunopathol. Pharmacol. 38, 3946320241309004. https:\/\/doi.org\/10.1177\/03946320241309004 (2024).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"61057_CR47","doi-asserted-by":"publisher","unstructured":"Choi, S-S., Lee, S-H. & Lee, K-A. A comparative study of hesperetin, hesperidin and hesperidin glucoside: Antioxidant, anti-inflammatory, and antibacterial activities in vitro. Antioxidants 11 https:\/\/doi.org\/10.3390\/antiox11081618 (2022).","DOI":"10.3390\/antiox11081618"},{"key":"61057_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"A Kumari","year":"2010","unstructured":"Kumari, A., Yadav, S. K. & Yadav, S. C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces. 75, 1\u201318. https:\/\/doi.org\/10.1016\/j.colsurfb.2009.09.001 (2010).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"61057_CR49","doi-asserted-by":"publisher","first-page":"111618","DOI":"10.1016\/j.mce.2022.111618","volume":"548","author":"JYL Chiang","year":"2022","unstructured":"Chiang, J. Y. L. & Ferrell, J. M. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol. Cell. Endocrinol. 548, 111618. https:\/\/doi.org\/10.1016\/j.mce.2022.111618 (2022).","journal-title":"Mol. Cell. Endocrinol."},{"key":"61057_CR50","doi-asserted-by":"publisher","unstructured":"Zhang, X., Lau, H. C. H. & Yu, J. Pharmacological treatment for metabolic dysfunction\u2013associated steatotic liver disease and related disorders: Current and emerging therapeutic options. Pharmacol. Rev. 77 https:\/\/doi.org\/10.1016\/j.pharmr.2024.100018 (2025).","DOI":"10.1016\/j.pharmr.2024.100018"},{"key":"61057_CR51","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965. https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4 (2015).","journal-title":"Lancet"},{"key":"61057_CR52","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield, G. M. et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148, 751\u2013761e8. https:\/\/doi.org\/10.1053\/j.gastro.2014.12.005 (2015).","journal-title":"Gastroenterology"},{"key":"61057_CR53","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","volume":"9","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis. Acta Pharm. Sin B. 9, 526\u2013536. https:\/\/doi.org\/10.1016\/j.apsb.2018.11.004 (2019).","journal-title":"Acta Pharm. Sin B"},{"key":"61057_CR54","doi-asserted-by":"publisher","first-page":"37234","DOI":"10.1038\/srep37234","volume":"6","author":"K Zhao","year":"2016","unstructured":"Zhao, K. et al. Activation of FXR protects against renal fibrosis via suppressing Smad3 expression. Sci. Rep. 6, 37234. https:\/\/doi.org\/10.1038\/srep37234 (2016).","journal-title":"Sci. Rep."},{"key":"61057_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","volume":"112","author":"PY Kwo","year":"2017","unstructured":"Kwo, P. Y., Cohen, S. M. & Lim, J. K. ACG clinical guideline: Evaluation of abnormal liver chemistries. Am. J. Gastroenterol. 112, 18\u201335. https:\/\/doi.org\/10.1038\/ajg.2016.517 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"61057_CR56","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/liv.15767","volume":"44","author":"LG Di Pasqua","year":"2024","unstructured":"Di Pasqua, L. G. et al. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob\/ob mouse model of NASH. Liver Int. Off J. Int. Assoc. Study Liver. 44, 214\u2013227. https:\/\/doi.org\/10.1111\/liv.15767 (2024).","journal-title":"Liver Int. Off J. Int. Assoc. Study Liver"},{"key":"61057_CR57","doi-asserted-by":"publisher","first-page":"e09979","DOI":"10.1016\/j.heliyon.2022.e09979","volume":"8","author":"DH Abou Baker","year":"2022","unstructured":"Abou Baker, D. H. et al. Biochemical and pharmacological prospects of Citrus sinensis peel. Heliyon 8, e09979. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09979 (2022).","journal-title":"Heliyon"},{"key":"61057_CR58","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1016\/j.transproceed.2019.02.059","volume":"51","author":"H-K Park","year":"2019","unstructured":"Park, H-K., Kang, S. W. & Park, M-S. Hesperidin ameliorates hepatic ischemia-reperfusion injury in Sprague-Dawley rats. Transpl. Proc. 51, 2828\u20132832. https:\/\/doi.org\/10.1016\/j.transproceed.2019.02.059 (2019).","journal-title":"Transpl. Proc."},{"key":"61057_CR59","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","volume":"342","author":"DS Pratt","year":"2000","unstructured":"Pratt, D. S. & Kaplan, M. M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl. J. Med. 342, 1266\u20131271. https:\/\/doi.org\/10.1056\/NEJM200004273421707 (2000).","journal-title":"N Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61057-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:44:30Z","timestamp":1791413070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61057-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61057"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61057-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the permission of the Hacettepe University Animal Experimentations Local Ethics Board (Meeting No. 2021\/10, Approval No. 2021\/10\u2009\u2212\u200903, File No. 2021\/75) and was performed in accordance with the ARRIVE guidelines 2.0.","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31352"}}